(Reuters) – The U.S. Food and Drug Administration (FDA) approved Japan-based Daiichi Sankyo Co’s treatment for newly diagnosed patients with an aggressive type of blood cancer, the company said on Thursday, pitting it against rival drugs from Novartis and Astellas Pharma.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
